Alkermes plc is a fully-integrated global biopharmaceutical company developing innovative medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Alkermes has a diversified portfolio of commercial medicines and a clinical pipeline of development candidates focused on central nervous system (CNS) disorders such as schizophrenia, depression, addiction and multiple sclerosis; and on cancer. Headquartered in Dublin, Ireland, Alkermes has a research and development (R&D) center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.
Alkermes strives to manage its business in a manner that promotes transparent governance, strong ethics, and environmental stewardship; maintains extensive patient, employee, and other stakeholder engagement; and helps Alkermes grow its business strategically, sustainably, and responsibly, including with respect to its environmental, social, and governance (ESG) impacts.
For more information, please visit Alkermes’ website at www.alkermes.com.